Effects of Sodium Arsenite on the Myocardial Differentiation in Mouse Embryonic Bodies

Area of Science:

• Toxicology
• Developmental Biology
• Cardiovascular Research

Background:

• Inorganic arsenic is a known human carcinogen and endocrine disruptor.
• Arsenic exposure during mammalian development can lead to fetal malformations and lethality.
• Embryonic bodies (EBs) offer a more physiologically relevant model for developmental toxicity studies than 2D cultures.

Purpose of the Study:

• To investigate the effects of sodium arsenite (SA) on early embryogenesis and cardiomyocyte differentiation in EBs.
• To elucidate the underlying mechanisms of SA toxicity, focusing on mitochondrial function.

Main Methods:

• Cultured EBs with three germ layers were treated with varying concentrations of sodium arsenite (SA).
• Cardiomyocyte differentiation was assessed by monitoring the initiation of beating.
• Mitochondrial morphology and function were analyzed using microscopy and gene expression analysis (Complex IV).

Main Results:

• SA treatment inhibited cardiomyocyte differentiation and delayed the initiation of beating in EBs.
• A low concentration (1 μM) of SA was found to delay but not completely abolish cardiomyocyte differentiation.
• SA exposure downregulated the transcription of the Complex IV gene and induced mitochondrial fission (increased number, decreased length).
• The arsenic chelator D-penicillamine partially restored EB beating but did not reverse mitochondrial dysfunction.

Conclusions:

• Sodium arsenite is a potent toxicant that induces mitochondrial damage, interfering with myocardial differentiation and overall embryogenesis.
• Even low-level, chronic exposure to SA during pregnancy can have irreversible adverse effects on fetal development via mitochondrial dysfunction.
• Increased awareness of SA exposure risks during pregnancy is crucial to prevent developmental abnormalities.